title: Expression of livin, survivin and caspase-3 in prostatic cancer and their clinical significance.
abstract: To explore the expressions level of Livin, Survivin and Caspase-3 in prostatic cancer and the relationship among the 3 proteins and the clinicopathological features as well as the correlation among them. Totally, 43 paraffin-embedded prostate cancer tissues obtained from patients who were performed with rectal prostate biopsy or excision and 17 paraffin-embedded prostatic hyperplasia tissues were collected. All the specimens were confirmed by pathology. Immunohistochemistry SP method was used to detect the expressions of Livin, Survivin and Caspase-3 in prostatic cancer compared to hyperplasia tissues. The positive expression rates of both Livin and Survivin in prostatic cancer tissue were higher than those in prostatic hyperplasia tissue (93.02% vs. 64.70%, P < 0.05; 83.72% vs. 35.29%, P < 0.01). However, the positive expression rate of Caspase-3 in prostatic cancer tissue was obviously lower than that in prostatic hyperplasia tissue (25.58% vs. 58.82%, P < 0.01). Both Livin and Survivin expressions in prostatic cancer tissue were related to pathological grading (Gleason scores) (X(2) = 14.000, P = 0.001), but not related to preoperative PSA, clinical stages and distant metastasis (P > 0.05). Capsase-3 expression in prostatic cancer tissue was related to pathological grading (Gleason scores) (X (2) = 14.000, P = 0.001) and clinical stages (X (2) = 4.896, P = 0.027), but not related to preoperative PSA and distant metastasis (P > 0.05). In prostatic cancer tissue, Livin expression had no correlation with Survivin expression (r = 0.127, P = 0.419 > 0.05), but negatively correlated with Caspase-3 expression (r = -0.497, P = 0.001). Survivin expression was negatively correlated with Caspase-3 expression (r = -0.354, P = 0.020). Livin, Survivin and Caspase-3 are closely related to the occurrence and development of prostatic cancer and which are expected to become new targets for diagnosis and treatment in future.
authors.affiliation: Department of Urology, The Second Hospital of Hebei Medical University Shijiazhuang 050000, Hebei, China.
authors.forename: Junfei
authors.initials: J
authors.lastname: Gu
authors.affiliation: Department of Urology, The Second Hospital of Hebei Medical University Shijiazhuang 050000, Hebei, China.
authors.forename: Lixin
authors.initials: L
authors.lastname: Ren
authors.affiliation: Department of Urology, The Second Hospital of Hebei Medical University Shijiazhuang 050000, Hebei, China.
authors.forename: Xiaolu
authors.initials: X
authors.lastname: Wang
authors.affiliation: Department of Urology, The Second Hospital of Hebei Medical University Shijiazhuang 050000, Hebei, China.
authors.forename: Changbao
authors.initials: C
authors.lastname: Qu
authors.affiliation: Department of Urology, The Second Hospital of Hebei Medical University Shijiazhuang 050000, Hebei, China.
authors.forename: Yong
authors.initials: Y
authors.lastname: Zhang
mesh_terms: D048868:Adaptor Proteins, Signal Transducing / Q000032:analysis*; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis* / Q000097:blood; D053148:Caspase 3 / Q000032:analysis*; D006801:Humans; D007150:Immunohistochemistry; D051034:Inhibitor of Apoptosis Proteins / Q000032:analysis*; D007610:Kallikreins / Q000097:blood; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009362:Neoplasm Metastasis; D009363:Neoplasm Proteins / Q000032:analysis*; D009367:Neoplasm Staging; D017430:Prostate-Specific Antigen / Q000097:blood; D011470:Prostatic Hyperplasia / Q000097:blood / Q000201:enzymology* / Q000473:pathology; D011471:Prostatic Neoplasms / Q000097:blood / Q000201:enzymology* / Q000473:pathology / Q000601:surgery; D000077022:Survivin
chemical_list: D048868:Adaptor Proteins, Signal Transducing; C107489:BIRC5 protein, human; C419866:BIRC7 protein, human; D014408:Biomarkers, Tumor; D051034:Inhibitor of Apoptosis Proteins; D009363:Neoplasm Proteins; D000077022:Survivin; C549870:KLK3 protein, human; D007610:Kallikreins; D017430:Prostate-Specific Antigen; C505407:CASP3 protein, human; D053148:Caspase 3
keywords: Prostatic cancer; caspase-3; correlation; livin; survivin
references.citation: CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29
references.pmid: 14974761
references.citation: Cancer Surv. 1997;29:305-27
references.pmid: 9338106
references.citation: Anticancer Res. 1998 Nov-Dec;18(6A):4347-53
references.pmid: 9891491
references.citation: Cell. 1999 Jan 22;96(2):245-54
references.pmid: 9988219
references.citation: Mol Cancer Ther. 2007 Jan;6(1):24-30
references.pmid: 17237263
references.citation: J Surg Res. 2007 Sep;142(1):184-94
references.pmid: 17603079
references.citation: Cell Cycle. 2008 Apr 15;7(8):1036-46
references.pmid: 18414036
references.citation: World J Gastroenterol. 2008 Oct 7;14(37):5749-54
references.pmid: 18837095
references.citation: BMC Cancer. 2009;9:125
references.pmid: 19397802
references.citation: Leuk Res. 2010 Jan;34(1):18-23
references.pmid: 20109966
references.citation: Cancer. 2010 Jun 1;116(11):2590-5
references.pmid: 20310055
references.citation: Mol Biol Rep. 2010 Jun;37(5):2241-7
references.pmid: 19690982
references.citation: Cell Death Differ. 2010 Oct;17(10):1613-23
references.pmid: 20395960
references.citation: Prostate. 2011 Jan 1;71(1):42-51
references.pmid: 20607788
references.citation: Asian Pac J Cancer Prev. 2012;13(6):2681-5
references.pmid: 22938441
references.citation: Med Oncol. 2014 May;31(5):941
references.pmid: 24696218